Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
ConditionDemodex Blepharitis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorGlaukos Corporation
About this trial
This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.
Eligibility criteria
Qualifiers
Signs of Demodex blepharitis in at least one eye
Best Spectacle Corrected Visual Acuity (BSCVA) of 20/80 Snellen or better in each eye
Disqualifiers
Presence of eczema or dermatitis in the ocular region of either eye
Use of lid hygiene products within 14 days of Screening
Active ocular infection or inflammation, other than blepharitis, in either eye at Screening
Women who are pregnant, planning a pregnancy, or nursing
Trial design
Treatments tested in this trial
- GLK-321 low dose BID
- GLK-321 mid dose BID
- GLK-321 high dose BID
- GLK-321 high dose QD
- Placebo BID
Treatment groups
250 Participants
are divided into 5 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov